Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors.
Ramón LecumberriPedro C Ruiz ArtachoInna TzoranBenjamin BrennerDominique Farge-BancelCihan AyVladimir RosaIria FranciscoLuis Manuel Hernández-BlascoJavier Trujillo-SantosManuel Monrealnull nullPublished in: Thrombosis and haemostasis (2022)
Patients with hematologic cancers, particularly multiple myeloma, and VTE had better outcomes than those with solid cancers. These findings are relevant for the interpretation of previous clinical trials and the design of future studies.